YURAK ISHEMIK KASALLIGIDA INTEGRIN GENLAR POLIMORFIZMI VA ERUVCHAN FIBRIN-MONOMER KOMPLEKSINING GIPERKOAGULYATSION SINDROM RIVOJLANISHIDAGI ROLI

Dildora Nasretdenova

Mualliflar

Dildora Nasretdenova Urganch davlat tibbiyot instituti «Ichki kasalliklar va dermatovenerologiya» kafedrasi Tibbiyot fanlari bo'yicha falsafa doktori (PhD), katta o'qituvchi ##default.groups.name.author##

Kalit so‘zlar:

yurak ishemik kasalligi, integrin genlar, ITGB3, ITGA2, polimorfizm

Abstrak

Ushbu maqolada yurak ishemik kasalligi (YIK) bilan og'riyotgan bemorlarda ikkita patogenetik muhim mexanizm — integrin genlar polimorfizmi va eruvchan fibrin-monomer kompleksi (EFMK) — birgalikda tahlil qilinadi. Maqsad: YIK bemorlarida ITGB3 (rs918, Leu59Pro T>C) va ITGA2 (rs1126643, 807C>T) genlarining alel chastotasini aniqlash, shuningdek EFMK ko'rsatkichining diagnostik va patogenetik ahamiyatini baholash. Material va usullar: Genotiplash 118 nafar YIK bemorida PCR-RFLP usulida amalga oshirildi; 32 nafar bemorning venoz qonida EFMK darajasi o'lchandi. Natijalar: ITGB3 rs918 mutant C alleli bemorlarning 45,8% ida, ITGA2 rs1126643 mutant T alleli 41,7% ida aniqlandi. EFMK o'rtacha darajasi 4,56 ± 0,36 mg/dl ni tashkil etdi; bemorlarning 18,75% ida me'yordan oshgan EFMK qayd etildi. Xulosa: Integrin polimorfizmlari trombotsit faolligini kuchaytirsa, EFMK oshishi koagulyatsion kaskad faollashuvini aks ettiradi — ushbu ikkala mexanizm sinergistik tarzda giperkoagulyatsion sindrom shakllanishiga zamin yaratadi. Ikkala biomarker YIK bemorlarida trombotik xavfni individuallashtirishda farmakogenetik va diagnostik ahamiyatga ega

##plugins.themes.default.displayStats.downloads##

##plugins.themes.default.displayStats.noStats##

Havolalar

1. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15–28.

2. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin αIIbβ3) odyssey. Blood. 2008;112(8):3011–3025.

3. Moshfegh K, et al. Two adjacent genetic polymorphisms within the receptor-binding domain of the β3-integrin gene are associated with different risks of thrombosis. Thromb Haemost. 1999;82(3):1211–1215.

4. Kunicki TJ, et al. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol. 2001;21(6):1132–1138.

5. Kadirova N.A., Nasretdenova D.O. Izuchenie chastoty polimorfizmov genov FBG i PAI-1 pri arterialnoy gipertenzii // Sbornik tezisov XXII Vserossiyskogo kongressa «Arterialnaya gipertoniya 2026». — 2026. — S. 16.

6. Barkazan Z.S., Momot A.P. Diagnostika i kontroliruemaya terapiya narusheniy gemostaza. — Moskva: N'yudiamed, 2008. — 292 s.

7. Weng Z, et al. Platelet function genetic polymorphisms and cardiovascular disease risk. J Thromb Thrombolysis. 2015;39(3):265–274.

8. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26(7):2181–2188